ASCO 2018 | Subcutaneous daratumumab: combining efficacy, safety & convenience
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities. In this video, recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL, Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, discusses the PAVO trial (NCT02519452) for a subcutaneous method of administering daratumumab. Daratumumab is combined with hyaluronidase, yielding improved convenience and safety compared to IV administration, and encouraging efficacy data.
Get great new content delivered to your inboxSign up